Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nuvaxovid COVID-19 Vaccine Wins EU Approval

Data On Efficacy Of Nuvaxovid Against Omicron Is Limited

Executive Summary

Initial doses of Novavax’s vaccine are expected to arrive in Europe in January.

You may also be interested in...



China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike

The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.

Coronavirus Notebook: UK Approves Novavax Vaccine, EMA Updates On Progress With Other Candidates

With the approval of Nuvaxovid, the UK and the EU now each have five COVID-19 vaccines at their disposal. Meanwhile, the European Medicines Agency has given an estimated timeline for the approval of candidate vaccines from Valneva and Sanofi Pasteur, and is looking at which therapeutics could be effective against the Omicron variant. Russia says its Sputnik V vaccine has now been granted full regulatory approval there.

COVID-19 Products Had Strong 2021, But Omicron Casts Shadow Over 2022

Evidence that the new variant dulls drugs and vaccines’ efficacy creates uncertainty for 2022, but new products are in the wings.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel